Skip to Main Content

Well, this is stunning: Looks like Grail, the Illumina spinout that’s working on an early blood-based screening test for cancer, will be raising a Series B round that clocks in at more than $1 billion.

The company just put out a statement that a number of undisclosed investors are seriously interested in doling out this cash. Fast Company last month had reported that the company was looking to raise $1.7 billion.

Unlock this article by subscribing to STAT+ and enjoy your first 30 days free!


Comments are closed.